LshCas13a/C2c2 (Leptotrichia shahii) (7D1-H7) Mouse mAb #43731
- WB
- IF
Supporting Data
| REACTIVITY | All |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 166 |
| Source/Isotype | Mouse IgG1 |
Application Key:
- WB-Western Blotting
- IF-Immunofluorescence
Species Cross-Reactivity Key:
- All-All Species Expected
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunofluorescence (Immunocytochemistry) | 1:50 - 1:200 |
Storage
Protocol
Specificity / Sensitivity
LshCas13a/C2c2 (Leptotrichia shahii) (7D1-H7) Mouse mAb recognizes transfected levels of total LshCas13a/C2c2 (Leptotrichia shahii) protein. This antibody may detect several non-specific bands of unknown origin in rat cell lines.
Species Reactivity:
All Species Expected
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of LshCas13a/C2c2 (Leptotrichia shahii) protein.
Background
CRISPR-Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins) are RNA-guided nuclease effectors that are utilized for precise genome editing in mammalian systems (1). Cas13 proteins are members of the Class 2 CRISPR-Cas system. Class 2 CRISPR systems, such as the well characterized Cas9, rely on single-component effector proteins to mediate DNA/RNA interference rather than the multi-Cas protein complexes that belong to the Class 1 systems (2). Evolutionarily, CRISPR-Cas proteins act as RNA-guided antiviral and anti-plasmid that protect prokaryotes from phage-mediated infections. RNA-guided CRISPR-Cas proteins can act on both DNA and RNA. Cas13 proteins act as RNA-guided RNA nucleases, disrupting phage infection by RNA cleavage. The CRISPR-Cas system is being used for nuclease-based gene-editing. Since the Cas13 proteins act on RNA rather than DNA, Cas13 proteins, coupled with the appropriate guide RNA, can be used to target specific RNA substrates, potentially replacing or complementing RNA interference approaches that interfere with transcript levels (3). Several Cas13 bacterial orthologs have been characterized for CRISPR-mediated mammalian RNA editing, including LshCas13a/C2c2 and PspCas13b derived from Leptotrichia shahii and Prevotella sp. P5–125, respectively (4-6).
- Cong, L. et al. (2013) Science 339, 819-23.
- Horvath, P. and Barrangou, R. (2010) Science 327, 167-70.
- Wang, Q. et al. (2019) Adv Sci (Weinh) 6, 1901299.
- East-Seletsky, A. et al. (2016) Nature 538, 270-273.
- Smargon, A.A. et al. (2017) Mol Cell 65, 618-630.e7.
- Cox, D.B.T. et al. (2017) Science 358, 1019-1027.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.